4.2 Article

PCDH19-related female-limited epilepsy: Further details regarding early clinical features and therapeutic efficacy

Journal

EPILEPSY RESEARCH
Volume 106, Issue 1-2, Pages 191-199

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2013.04.005

Keywords

Antiepileptic drugs; Early diagnosis; Genetic analysis; Multiplex ligation-dependent probe amplification; Seizure clusters; Treatment

Funding

  1. Japan Society for the Promotion of Science (JSPS) [21249062, 23659529, 22791011, 24791095]
  2. Ministry of Education, Culture, Sports, Science and Technology
  3. Research Grants for Nervous and Mental Disorder [21B-5]
  4. Health and Labour Science Research Grants [21210301, KB220001]
  5. Ministry of Health, Labour and Welfare [H22-Nanji-Ippan-49]
  6. Japan Science and Technology Agency (JSP)
  7. Japan Epilepsy Research Foundation
  8. Research Grants for Central Research Institute for the Molecular Pathomechanisms of Epilepsy of Fukuoka University and Recommended Projects from Fukuoka University [117016]
  9. Grants-in-Aid for Scientific Research [24791095, 22791011] Funding Source: KAKEN

Ask authors/readers for more resources

Abnormalities in the protocadherin 19 (PCDH19) gene cause early-onset epilepsy exclusively in females. We aimed to explore the genetic and clinical characteristics of PCDH19-related epilepsy by focusing on its early features and treatment efficacy. PCDH19 was analyzed in 159 Japanese female patients with early-onset epilepsy via direct sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis. We identified 17 patients with PCDH19 abnormalities: point mutations were observed in 14 patients and whole PCDH19 deletions were detected in 3 patients. One affected sister of a proband with a mild phenotype was also analyzed. The frequency of PCDH19 deletion among all probands identified in Japan was 12.5% (3/24, including 7 probands reported previously by us). Clinical features included early onset (mean age at onset, 8.6 months), recurrent clusters of brief seizures (17118), fever sensitivity (18/18), tonic seizures (13/18, probably including focal tonic seizures), tonic clonic seizures (8/18), focal seizures often with subsequent generalization (17/18), intellectual disabilities (15/18), and autistic traits (13/18). Three patients exhibited delay in motor milestones before seizure onset. In 16 patients, seizures appeared in clusters from the onset of the disease. Among 6 patients for whom detailed information at onset was available, 2 onset patterns were identified: a biphasic course of short seizure clusters (each within days) in 2 patients and a prolonged course of clusters (from weeks to a month) in 4 patients. In both cases, initial seizures started during fever and transiently disappeared with the decline of fever; however, afebrile clusters recurred. In the former patients, motor development was delayed before onset, and seizures appeared in strong clusters from the onset of the disease. In the latter patients, initial development was normal and initial seizures were mild, but were followed by strong clusters lasting several weeks, even without fever. Treatment using phenytoin, potassium bromide, and clobazam showed high efficacy. Although focal seizures were the main feature in PCDH19-epilepsy, the efficacy of carbamazepine was poor. This study highlighted the significance of PCDH19 deletion, a unique pattern of initial seizure clusters, and the efficacy of antiepileptic drugs. Our data will facilitate early diagnosis and development of a treatment strategy for better clinical management of patients with PCDH19-related epilepsy. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available